These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 12955350)

  • 21. The predictive value of epitope analysis in highly sensitized patients awaiting renal transplantation.
    Laundy GJ; Bradley BA
    Transplantation; 1995 Apr; 59(8):1207-13. PubMed ID: 7537397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural epitope matching for HLA-alloimmunized thrombocytopenic patients: a new strategy to provide more effective platelet transfusion support?
    Duquesnoy RJ
    Transfusion; 2008 Feb; 48(2):221-7. PubMed ID: 18005328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. II. Verification of the algorithm and determination of the relative immunogenicity of amino acid triplet-defined epitopes.
    Duquesnoy RJ; Marrari M
    Hum Immunol; 2002 May; 63(5):353-63. PubMed ID: 11975979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Refinement of permissible HLA mismatches.
    Takemoto S; Terasaki PI
    Clin Transpl; 1994; ():451-66. PubMed ID: 7547575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Critical evaluation of the amino acid triplet-epitope matching concept in cadaver kidney transplantation.
    Laux G; Mytilineos J; Opelz G
    Transplantation; 2004 Mar; 77(6):902-7. PubMed ID: 15077035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transplantation of highly sensitized patients on the basis of acceptable HLA-A and B mismatches.
    Claas FH; de Waal LP; Beelen J; Reekers P; Berg-Loonen PV; de Gast E; D'Amaro J; Persijn GG; Zantvoort F; van Rood JJ
    Clin Transpl; 1989; ():185-90. PubMed ID: 2487564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repeating HLA antigen mismatches in renal retransplants--a second class mistake?
    Cecka JM; Terasaki PI
    Transplantation; 1994 Feb; 57(4):515-9. PubMed ID: 8116035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HLA amino acid residue matching.
    Takemoto SK
    Clin Transpl; 1996; ():397-425. PubMed ID: 9286585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiscreen serum analysis of highly sensitized renal dialysis patients for antibodies toward public and private class I HLA determinants. Implications for computer-predicted acceptable and unacceptable donor mismatches in kidney transplantation.
    Duquesnoy RJ; White LT; Fierst JW; Vanek M; Banner BF; Iwaki Y; Starzl TE
    Transplantation; 1990 Sep; 50(3):427-37. PubMed ID: 2402792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential immunogenicity of HLA mismatches in clinical transplantation.
    Claas FH; Dankers MK; Oudshoorn M; van Rood JJ; Mulder A; Roelen DL; Duquesnoy RJ; Doxiadis II
    Transpl Immunol; 2005 Aug; 14(3-4):187-91. PubMed ID: 15982562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The number of amino acid residues mismatches correlates with flow cytometry crossmatching results in high PRA renal patients.
    Lobashevsky AL; Senkbeil RW; Shoaf JL; Stephenson AK; Skelton SB; Burke RM; Deierhoi MH; Thomas JM
    Hum Immunol; 2002 May; 63(5):364-74. PubMed ID: 11975980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients.
    van den Berg-Loonen EM; Billen EV; Voorter CE; van Heurn LW; Claas FH; van Hooff JP; Christiaans MH
    Transplantation; 2008 Apr; 85(8):1086-90. PubMed ID: 18431226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of HLAMatchmaker algorithm in identifying acceptable HLA mismatches for thrombocytopenic patients refractory to platelet transfusions.
    Brooks EG; MacPherson BR; Fung MK
    Transfusion; 2008 Oct; 48(10):2159-66. PubMed ID: 18631168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HLA compatibility and organ transplant survival. Collaborative Transplant Study.
    Opelz G; Wujciak T; Döhler B; Scherer S; Mytilineos J
    Rev Immunogenet; 1999; 1(3):334-42. PubMed ID: 11256424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B cell positive cross-match not due to anti-HLA Class I antibodies and first kidney graft outcome.
    Praticò-Barbato L; Conca R; Magistroni P; Leonardi G; Oda A; Rosati F; Leone E; Tacconella M; Roggero S; Segoloni GP; Amoroso A
    Transpl Immunol; 2008 Jul; 19(3-4):238-43. PubMed ID: 18675725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm.
    Duquesnoy RJ
    Hum Immunol; 2002 May; 63(5):339-52. PubMed ID: 11975978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The OPTN/UNOS Renal Transplant Registry.
    Cecka JM
    Clin Transpl; 2005; ():1-16. PubMed ID: 17424721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A lifetime versus a graft life approach redefines the importance of HLA matching in kidney transplant patients.
    Meier-Kriesche HU; Scornik JC; Susskind B; Rehman S; Schold JD
    Transplantation; 2009 Jul; 88(1):23-9. PubMed ID: 19584676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The HLA-matching effect in different cohorts of kidney transplant recipients.
    Terasaki PI
    Clin Transpl; 2000; ():497-514. PubMed ID: 11512361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using the mimetic epitope concept to find a possible way to widen the graft-survival difference between matched and mismatched renal transplants.
    Sasaki N; Idica A; Hall B; Terasaki PI
    Clin Transpl; 2008; ():241-52. PubMed ID: 19711515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.